|
9:30–10:00 am |
Association of Autistic Spectrum Disorder and MMR Vaccine: A Systematic Review of Current Epidemiological Evidence Kumanan Wilson, M.D., M.Sc., Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Canada |
|
10:00–10:30 am |
Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects Frank DeStefano, M.D., Centers for Disease Control and Prevention |
|
10:30–10:45 am |
Break |
|
10:45–11:15 am |
Exposure to Thimerosal-Containing Vaccines in U.K. Children and Autism Dr. Elizabeth Miller, Head, Immunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London |
|
11:15–11:45 am |
Vaccine Safety Datalink Study: Autism Outcome Robert L. Davis, M.D., M.P.H., University of Washington Group Health, Cooperative Departments of Pediatrics Center for Health Studies and Epidemiology |
|
11:45–12:15 pm |
Study of the Association Between Thimerosal-Containing Vaccine and Autism in Denmark Anders Peter Hviid, M.Sc., Department of Epidemiology Research, State Serum Institute, Copenhagen, Denmark |
|
12:15–12:45 pm |
Autism and Thimerosal-Containing Vaccines: Analysis of the Vaccine Adverse Events Reporting System (VAERS) Mark R. Geier, M.D., Ph.D., President, The Genetic Centers of America David Geier, President of MedCon |
|
12:45–1:45 pm |
Lunch |